Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 26 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... December 17, 2020 Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma May 7, 2021 NHS lung cancer patients in England to get early access to... September 9, 2021 EMA Recommends Extension of Indications for Cabozantinib July 10, 2025 Load more HOT NEWS Living with a stoma: Neil and Lindsay share their experiences after... ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... Gentle regular exercise could reduce the risk of liver cancer in... A More Treatable Kind of Metastatic Cancer?
